We understand the difficulty involved in developing scalable, closed and controlled processes for pluripotent stem cell (PSC) derived products. As one of our challenge themes, we are determined to continue using our extensive experience in allogeneic therapies to create robust processes that maximise the therapeutic potential of PSCs.
We have developed an end-to-end closed iPSC expansion process for process intensification that is easily translatable and demonstrates a means of repeatable iPSC expansion.
